WuXi AppTec and Juno Therapeutics' immuno-oncology joint venture is reportedly seeking $250m to $300m in a Hong Kong offering.

The solar tracking technology provider is aiming for $207m in an IPO on Shanghai's Star Market having raised money in a Risen Solar-backed round last year.

Existing investors including Foxconn, SK Telecom and iA Financial could buy up to $80m of shares in the medical imaging system developer's initial public offering.

Eberhard Karls University of Tübingen's messenger RNA drug developer CureVac priced the offering at the top of its range.

GlaxoSmithKline Eli Lilly and Genmab-backed messenger RNA drug developer CureVac priced the offering at the top of its range.

Tencent is buying $160m of shares in the real estate platform's initial public offering, which also provides an exit for SoftBank Vision Fund.

SAIC Capital has scored an exit less than two years after it invested in the now publicly-listed intelligent manufacturing technology provider.

Cofco and several banks will get the chance to exit Ping An's online lending spinoff, which is targeting $3bn in a US initial public offering.

The Humana-backed primary care provider has closed its initial public offering after its share price more than doubled post-IPO.

The cancer treatment developer floated in the middle of its range following $175m in venture funding from investors including Novo.